Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.
about
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipientsMetabolic consequences of modern immunosuppressive agents in solid organ transplantationSkin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repairThe use of novel diagnostics to individualize immunosuppression following transplantationCD45RA distinguishes CD4+CD25+CD127-/low TSDR demethylated regulatory T cell subpopulations with differential stability and susceptibility to tacrolimus mediated inhibition of suppression.Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study.mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.Effect of tolerance versus chronic immunosuppression protocols on the quality of life of kidney transplant recipients.Renal transplantation: relationship between hospital/surgeon volume and postoperative severe sepsis/graft-failure. a nationwide population-based study.Chronic graft loss and death in patients with post-transplant malignancy in living kidney transplantation: a competing risk analysis.Association of HLA mismatch with death with a functioning graft after kidney transplantation: a collaborative transplant study report.Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression.Effect of left atrial and ventricular abnormalities on renal transplant recipient outcome-a single-center study.Vector-free and transgene-free human iPS cells differentiate into functional neurons and enhance functional recovery after ischemic stroke in mice.Weight gain, overweight and obesity in solid organ transplantation--a study protocol for a systematic literature review.Incidence and risk factors of herpes zoster among adult renal transplant recipients receiving universal antiviral prophylaxis.New-Onset Diabetes Mellitus After Transplantation in a Cynomolgus Macaque (Macaca fasicularis).Tolerance-inducing strategies in islet transplantationIncidence of malignancy after living kidney transplantation: a multicenter study from iran.General method for the synthesis of salicylic acids from phenols through palladium-catalyzed silanol-directed C-H carboxylationIs HRQOL in dialysis associated with patient survival or graft function after kidney transplantation?Helios expression and Foxp3 TSDR methylation of IFNy+ and IFNy- Treg from kidney transplant recipients with good long-term graft functionBD750, a benzothiazole derivative, inhibits T cell proliferation by affecting the JAK3/STAT5 signalling pathwayUse of hematopoietic cell transplants to achieve tolerance in patients with solid organ transplantsRace, Calcineurin Inhibitor Exposure, and Renal Function After Solid Organ Transplantation.Relationship between immunosuppressive medications adherence and quality of life and some patient factors in renal transplant patients in Iran.Clinical associations between renal dysfunction and vascular events: A literature review.Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigensT-regulatory cell-mediated immune tolerance as a potential immunotherapeutic strategy to facilitate graft survivalDonor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.Biological agents in kidney transplantation: belatacept is entering the field.CD4+ regulatory T cells in solid organ transplantation.Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation.Principles of a new treatment algorithm in multiple sclerosis.Neovascular age-related macular degeneration: opportunities for development of first-in-class biopharmaceuticals.Therapy for sarcoidosis: evidence-based recommendations.An evaluation of sirolimus in renal transplantation.Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.Belatacept utilization recommendations: an expert position.
P2860
Q24187213-17F0B097-8ECD-427B-B988-64A62E91A3D4Q26746936-D54181E4-9546-4C88-A1F0-87FC90F50C90Q26822549-F2761A01-C8DE-447A-9797-F0053D0E129DQ26864686-7FD44C18-4862-4E18-A093-09C2189ACA49Q30489628-F212C01B-2387-4D8C-9A2B-D32966122E8CQ31138722-B2043D9D-BD38-4493-8162-551AEEE421CEQ33414365-D657237E-686F-430F-BC99-B59E1D746995Q33424013-03F75C76-E797-49D8-BBC7-FAD3729A9407Q33468225-622DC2B6-F861-49D7-878B-BD3DB39F2B55Q33843873-6159D54F-E93D-4228-81E5-9B72C9CCAD54Q33876782-CF1301CC-89CB-45D5-A89A-17664A6B7B5AQ34294557-2E7E0861-76A5-4A06-8A21-8CDBF325709DQ34496604-452F7B58-2936-4736-8A14-E2E152F920EBQ34667281-7C716AC5-01F7-4009-90D9-411E875D907FQ34745357-7EC46E6B-B66B-4528-BF50-5E2FDEC84E62Q35060274-9E2FD9CF-92DD-4966-A19A-5009C5593279Q35708692-B153A347-95C8-47FE-B1AB-19F88BDEA2B2Q35996489-E16DE1D0-22B7-4803-8BBD-3A07B1419955Q36004707-CC55FC77-415C-44DE-A8F3-2FC9BDFF49EFQ36037651-E0EB00A7-F87D-430D-8614-D41445429C8EQ36047548-C473FCBC-96F2-4222-8104-8D684AA724CAQ36085258-61347E0E-A2E3-41D9-BDBA-3519297814DAQ36309090-55DE94C6-50B7-4001-BF76-359182DD26A3Q36629277-0E3A8004-373D-451D-A81F-C43B4820388BQ36727857-B6195CF3-D85B-46D3-9730-F3E10E4E5417Q36761340-5FE911BB-6E86-4856-9D46-A1E6F6C6CA27Q36780342-1737553E-8B04-4C22-8E58-91A3C4DFF625Q36925534-0B9CF111-7631-4546-9C89-271DD37E38B4Q37040508-00E1CD6C-29C9-40A0-B197-A20A70003626Q37059199-58960FD8-76AC-4A5A-BF33-A41D0D211436Q37443674-CFFCE468-C112-4832-8C98-E24058316C37Q37781355-65B8B1A0-7087-4C44-85C7-C16E2794EF2FQ37794623-0E18FE65-398E-4595-BEBD-D435FF3551A6Q37818197-E698B515-60C9-41BB-B32A-D059422A73A5Q37849763-3E57B6ED-F729-4123-991E-2CCF3DB66A1DQ37882685-6FF4CB59-D3DB-4ED0-AA97-36089091A40FQ37965606-85CA2B5D-B641-4B0D-87C6-DB01BF018E06Q38038696-F60F9E39-0F94-4EF5-9AFE-E9513478FED5Q38049346-F8948DB7-BDE1-41AF-9E9F-E35FADACCA4BQ38064538-06BD2EAF-5C06-4688-947E-633DA1AE4DF8
P2860
Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Immunosuppressive drugs in kid ...... ase, malignancy and infection.
@ast
Immunosuppressive drugs in kid ...... ase, malignancy and infection.
@en
Immunosuppressive drugs in kid ...... ase, malignancy and infection.
@nl
type
label
Immunosuppressive drugs in kid ...... ase, malignancy and infection.
@ast
Immunosuppressive drugs in kid ...... ase, malignancy and infection.
@en
Immunosuppressive drugs in kid ...... ase, malignancy and infection.
@nl
prefLabel
Immunosuppressive drugs in kid ...... ase, malignancy and infection.
@ast
Immunosuppressive drugs in kid ...... ase, malignancy and infection.
@en
Immunosuppressive drugs in kid ...... ase, malignancy and infection.
@nl
P2860
P1433
P1476
Immunosuppressive drugs in kid ...... ase, malignancy and infection.
@en
P2093
Roberto Marcén
P2860
P304
P356
10.2165/11319260-000000000-00000
P577
2009-11-01T00:00:00Z
P5875
P6179
1040624004